VANECK VECTORS ETF TR's ticker is GDX and the CUSIP is 92189F106. A total of 377 filers reported holding VANECK VECTORS ETF TR in Q3 2017. The put-call ratio across all filers is 1.17 and the average weighting 0.5%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2017 | $249,000 | – | 11,280 | – | 0.20% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Memorial Sloan Kettering Cancer Center | 738,500 | $20,220,000 | 66.82% |
| Baymount Management LP | 145,000 | $3,970,000 | 28.08% |
| New Harbor Financial Group, LLC | 1,371,341 | $37,547,000 | 18.51% |
| New Harbor Financial Group, LLC | 1,291,700 | $35,366,000 | 17.44% |
| MKP Capital Management, L.L.C. | 1,500,000 | $41,070,000 | 13.74% |
| Windmill Hill Asset Management Ltd | 844,600 | $23,125,000 | 11.94% |
| Hollow Brook Wealth Management LLC | 768,567 | $21,043,000 | 11.57% |
| Grand Central Investment Group | 261,915 | $7,171,000 | 10.33% |
| Point72 Europe (London) LLP | 1,467,000 | $40,166,000 | 8.50% |
| Slate Path Capital LP | 4,600,000 | $125,948,000 | 7.87% |